Disease

New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection

Retrieved on: 
Wednesday, January 19, 2022 - 10:01pm
FDA, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Patient, File, Private Securities Litigation Reform Act, SEC, BLA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, David Berry (inventor), Yale School of Medicine, Spore, The New England Journal of Medicine, Safety, Growth, NEJM, Breakthrough therapy, Firmicutes, Disease, Variometer, Graft-versus-host disease, AGAF, Recurrence, CDI, Ulcerative colitis, U.S. Securities and Exchange Commission, Nasdaq, Tissue, Clostridioides difficile infection, Therapy, FACG, Orphan drug, Subclinical infection, Quality of life, MD, Risk, Food, FDA, Security (finance), Pharmaceutical industry, Serica

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication in the New England Journal of Medicine (NEJM) of data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for the treatment of recurrent C. difficile infection (rCDI).

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication in the New England Journal of Medicine (NEJM) of data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for the treatment of recurrent C. difficile infection (rCDI).
  • The SER-109 ECOSPOR III Phase 3 study ( ClinicalTrials.gov identifier: NCT03183128) was a multicenter, randomized, placebo-controlled study.
  • In May 2021, Seres presented 24-week clinical data from the study that demonstrated significantly reduced recurrence rates compared to placebo.
  • The SER-109 program is being advanced to reduce the recurrence of C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic.

National Headache Foundation Position Statement on the Treatment of Migraine

Retrieved on: 
Wednesday, January 19, 2022 - 8:13pm
Disability, Education, Awareness, Research, Patient, Vertigo, HCU, Dizziness, Phonophobia, Standing, Migraine, Human, Population, Contraindication, NHF, Nausea, ER, Neutralizing antibody, Weight gain, Disease, Tolerability, GLOBE, Language, Positive statement, Headache, Goal, Tremor, Pain, Heart, Tinnitus, Work, Bradycardia, Risk, CGRP, Topiramate, FDA, Chronic kidney disease, Practitioner, Vomiting, Photophobia, Pharmaceutical industry, Health insurance, Medicine, Risk management, Residential care

Chicago, IL, Jan. 19, 2022 (GLOBE NEWSWIRE) -- For more than 50 years, the National Headache Foundation (NHF) has been the voice for more than 40 million American adults with migraine.

Key Points: 
  • Chicago, IL, Jan. 19, 2022 (GLOBE NEWSWIRE) -- For more than 50 years, the National Headache Foundation (NHF) has been the voice for more than 40 million American adults with migraine.
  • Unfortunately, the current care models adopted by payers (health insurance) have not kept pace with the many advances in treatment.
  • The vision of the National Headache Foundation (NHF) is a world without headache.
  • In the future, NHF will expand upon this Position Statement and propose specific treatment guidelines.

Dole Affiliate Receives Social Responsibility in Action Award in Costa Rica

Retrieved on: 
Wednesday, January 19, 2022 - 9:58pm
Retail, Agriculture, Natural Resources, Food, Beverage, People, Commerce, Chamber of commerce, Research, Disability, Gaps, Drinking water, Standard Fruit Company, Disease, Solution, NGO, Health, Housing, Industry, Program, Education, Agriculture, Work, Multimedia, University, Workforce, Food, Nature, Social responsibility, Management, Horticulture, COVID-19, Retail, Agriculture, Natural Resources, Food, Beverage

The American-Costa Rican Chamber of Commerce (AmCham) recognized Dole through its daughter company, Standard Fruit Company de Costa Rica S.A., with the Social Responsibility in Action Award in the Employees Category for their project "De la Mano con Dole" which loosely translates to "Hand-in-Hand with Dole".

Key Points: 
  • The American-Costa Rican Chamber of Commerce (AmCham) recognized Dole through its daughter company, Standard Fruit Company de Costa Rica S.A., with the Social Responsibility in Action Award in the Employees Category for their project "De la Mano con Dole" which loosely translates to "Hand-in-Hand with Dole".
  • This year marks the 25th anniversary of the award which was given December 8, 2021.
  • Dole is the first agribusiness company in the world to apply the bMPI methodology to address the challenges of social development.
  • In 2020, Dole introduced its three-pillared Sustainability Framework, The Dole Way , and its ongoing commitment For Food, For Nature and For People.

BiomeBank Appoints Ex-Ellerston Capital CIO and BlackRock North Asia Director as Chair to Accelerate Commercialisation Strategy

Retrieved on: 
Wednesday, January 19, 2022 - 7:58pm
Biotechnology, General Health, Health, Clinical Trials, Foundation, CEO, Disease, COVID-19 pandemic in North Asia, Microbiology, Company, Quality of life, TGA, Multimedia, Ecology, Board, Machine learning, Nightclub, Renewable energy, Pharmaceutical industry

BiomeBank today announces Mr Chris Hall as the new Chair for the clinical stage biotechnology company, having recently served as Chief Investment Officer of Ellerston Capital.

Key Points: 
  • BiomeBank today announces Mr Chris Hall as the new Chair for the clinical stage biotechnology company, having recently served as Chief Investment Officer of Ellerston Capital.
  • Prior to this, Mr Hall served as Managing Director of Blackrock Asset Management (North-Asia Ltd).
  • View the full release here: https://www.businesswire.com/news/home/20220119005391/en/
    Mr Hall succeeds Dr Stephen Rodda, who recently retired having served as the BiomeBank Chair since 2019.
  • BiomeBank Chief Executive Officer, Mr Thomas Mitchell said: Were thrilled to welcome Mr Hall as the new Chair of BiomeBank.

PROJECT ON FAIR REPRESENTATION WARNS NEW YORK DEPARTMENT OF HEALTH ABOUT RACIALLY DISCRIMINATORY PRIORITIZATION OF COVID-19 TREATMENTS

Retrieved on: 
Wednesday, January 19, 2022 - 8:22pm
COVID-19, Therapy, Color, Risk, Letter, 2009 Davis Cup, State, Skin, Policy, New York State Department of Health, Death, Disease, C. Boyden Gray, Department

AUSTIN, Texas, Jan. 19, 2022 /PRNewswire/ --Late yesterday, the Project on Fair Representation sent a letter to New York Department of Health Acting Commissioner Mary T. Basset warning the Department about serious legal problems in the Department's new racially discriminatory guidance on the prioritization of COVID-19 treatments.

Key Points: 
  • AUSTIN, Texas, Jan. 19, 2022 /PRNewswire/ --Late yesterday, the Project on Fair Representation sent a letter to New York Department of Health Acting Commissioner Mary T. Basset warning the Department about serious legal problems in the Department's new racially discriminatory guidance on the prioritization of COVID-19 treatments.
  • The letter notes that the Department's policy already has resulted in a lawsuit and warns the State will surely be sued again if it continues to prioritize treatments for certain racial and ethnic groups over others.
  • Edward Blum, president of the Project on Fair Representation said, "if permitted to continue, this policy will lead to needless loss of life and will illegally perpetuate immoral racial categories."
  • The shortage of COVID-19 therapeutics is bad enoughNew Yorkers of all races deserve better than having these lifesaving treatments rationed based on the color of their skin."

Awakn Life Sciences Signs MOU with Maps

Retrieved on: 
Wednesday, January 19, 2022 - 12:30pm
Disability, KARE, Forward-looking statement, PTSD, Research, FSE, News, Alcoholism, Clinical trial, Multidisciplinary Association for Psychedelic Studies, Ketamine, Addiction, MDMA, Safety, University, CEO, MAPS, Disease, UoE, American Journal, Psychiatry, Reduction, The American Journal of Psychiatry, Phrase, AUD, Company, Diagnosis, Education, Conditional sentence, Therapy, Family, Charity Navigator, NEO, Partnership, Pharmaceutical industry, Psychopharmacology

Agreement to Explore a Partnership for MDMA-Assisted Therapy for Treatment of Alcohol Use Disorder in Europe

Key Points: 
  • Under the terms of this MOU, Awakn will explore a data licensing agreement with MAPS to support Awakn's Phase IIb and planned Phase III studies for MDMA-assisted therapy for AUD in Europe.
  • Awakn and MAPS will also assess a partnership to secure marketing authorisation/regulatory approval for the ethical commercialization of MDMA-assisted therapy for the treatment of AUD in Europe.
  • "We're delighted to be entering into this MoU with AWAKN which holds great promise for people suffering from AUD."
  • About Awakn Life Sciences Corp.
    Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to better treat addiction.

Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study

Retrieved on: 
Wednesday, January 19, 2022 - 1:06am
People, Biomarker, Research, Washington University School of Medicine, Dementia, Tau, Seed, University College London, DIAD, Population, Safety, Domination, BAN2401, Disease, Solution, Parent, Tauopathy, Risk, Alzheimer's disease, Amyloid, Brain, Rapunzel's Tangled Adventure (season 2), Neurology, Amnesia, Amyloid beta, Partnership, Pharmaceutical industry, Medical imaging, Vaccine, Eisai

The study will assess the effect of Eisai's investigational anti-microtubule binding region (MTBR) tau antibody E2814, in dominantly inherited Alzheimer's disease (DIAD).

Key Points: 
  • The study will assess the effect of Eisai's investigational anti-microtubule binding region (MTBR) tau antibody E2814, in dominantly inherited Alzheimer's disease (DIAD).
  • In March 2021, the DIAN-TU selected E2814, which was created from a research collaboration between Eisai and University College London, as the first investigational medicine among anti-tau drugs for the Tau NexGen study.
  • With increasing evidence from clinical studies showing that targeting amyloid can reduce biomarkers of AD, the Tau NexGen clinical trial leaders selected Eisai's investigational anti-Abeta protofibril antibody lecanemab (BAN2401) as the background anti-amyloid therapy, and the study design was amended in November 2021.
  • In the Tau NexGen study, symptomatic participants will be administered anti-amyloid beta (Abeta) protofibril antibody lecanemab for six months before being randomly assigned to also receive the anti-tau drug or a placebo.

Genetic Technologies Reports Q2 FY22 Cash Flow Results

Retrieved on: 
Wednesday, January 19, 2022 - 2:00pm
Ageing, CMS, Vaccination, Research, Patient, UK Biobank, Center, Korea Disease Control and Prevention Agency, Colorectal cancer, NATA, Documentation, National public health institutes, Breast cancer, National, COVID-19, Population, Partnership, Growth, Calibration, Disease, Prostate cancer, Poster, Public health, Acquisition, DTC, Biobank, Health, IBX, Direct, Marketing, Type 2 diabetes, Company, Risk assessment, Single-nucleotide polymorphism, PLOS, Genetypes, Precision medicine, Certification, Risk, Coronary artery disease, CIT, Laboratory, Genetic testing, Omicron, Ovarian cancer, Woman, Awareness, Pharmaceutical industry, Sales, Birth control, Medical device, European

Emergence of new strains of COVID-19, such as Omicron, highlight the importance and utility of GENEs COVID-19 Risk Test.

Key Points: 
  • Emergence of new strains of COVID-19, such as Omicron, highlight the importance and utility of GENEs COVID-19 Risk Test.
  • As part of the EasyDNA integration, the Company announced the launch of the geneType rebrand in November 2021.
  • Total cash receipts for the quarter from EasyDNA were A$1.8 million in line with acquisition expectations.
  • The Company will provide an investor webinar to discuss the quarterly results.

Yumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739  

Retrieved on: 
Wednesday, January 19, 2022 - 12:30pm
Neurodegeneration, Patient, SCD, Cognition, Clinical trial, Private Securities Litigation Reform Act, FTLD, Fatty acid desaturase, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neurotoxicity, COVID-19, Safety, Growth, Death, Disease, GLOBE, IND, Movement, U.S. Securities and Exchange Commission, Traffic barrier, Industry, Therapy, Phrase, Company, ALS, Data collection, Neuron, Toxicity, Risk, Food, Muscle atrophy, Compte rendu, FDA, Trial of the century, Amyotrophic lateral sclerosis, Pharmaceutical industry, Yuman–Cochimí languages

The FDA has not halted all clinical programming and is permitting the Companys planned single dose clinical trial to proceed.

Key Points: 
  • The FDA has not halted all clinical programming and is permitting the Companys planned single dose clinical trial to proceed.
  • The partial clinical hold suspends initiation of multiple dose clinical trials in the U.S. until the FDAs questions have been addressed.
  • Yumanity anticipates working closely with the FDA to adequately address their concerns.
  • Yumanity Therapeutics explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

NRC Health Annual Consumer Trends Report Shows Declining Care Deferment, Rising Mental Health Challenges and Gaps in Telehealth

Retrieved on: 
Wednesday, January 19, 2022 - 3:00pm
Ophthalmology, United States Public Health Service, Survival, Patient, Internal medicine, Nursing, Annual report, Center, Korea Disease Control and Prevention Agency, Trial balance, COVID-19, Adoption, Database, NASDAQ, Dermatology, Physician, Disease, Mental health, GLOBE, BMI, Anxiety, Health care, Health, Time, Intelligence, Social, Industry, Lists of diseases, Counselor, NRC, Telehealth, Empathy, Trust, National Research Corporation, Body mass index, Practitioner, Hospital, Organization, Family, Pharmaceutical industry, Medicine, Health insurance

LINCOLN, Neb., Jan. 19, 2022 (GLOBE NEWSWIRE) -- NRC Health , the leading provider of in-depth customer intelligence in healthcare, today released its 2022 Healthcare Consumer Trends Report .

Key Points: 
  • LINCOLN, Neb., Jan. 19, 2022 (GLOBE NEWSWIRE) -- NRC Health , the leading provider of in-depth customer intelligence in healthcare, today released its 2022 Healthcare Consumer Trends Report .
  • The fourth annual report captures evolving consumer sentiments and provides insight into how healthcare organizations can navigate the next year successfully amid the ongoing COVID-19 pandemic.
  • Left untreated, many conditions are likely to deteriorate, leading to serious adverse outcomes that health systems may not be able to treat.
  • This increased frequency indicates that mental health services and resources, including telehealth behavioral services, are critical, particularly among populations disproportionately affected by COVID-19.